Ligand Pharmaceuticals market cap LGND
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $6.1B
- Highest close in our data
- $6.4B
- Oct 2026
Ligand Pharmaceuticals is worth $6.1B at the close on Nov 2, 2026, at $307.02 a share.
That is up 54% over the last year and up 284% over five years.
Its highest close in our data was $6.4B in Oct 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $6.1B | $3.6B | $6.4B | +59% |
| 2025 | $3.9B | $1.9B | $4B | +87% |
| 2024 | $2.1B | $1.2B | $2.4B | +66% |
| 2023 | $1.2B | $860.3M | $1.4B | +10% |
| 2022 | $1.1B | $816.6M | $1.5B | −30% |
| 2021 | $1.6B | $1.1B | $2B | +61% |
| 2020 | $998.3M | $687.8M | $1.2B | −15% |
| 2019 | $1.2B | $1B | $1.8B | −35% |
| 2018 | $1.8B | $1.8B | $3.6B | −0% |
| 2017 | $1.8B | $1.3B | $1.9B | +36% |
| 2016 | $1.3B | $1.1B | $1.8B | −2% |
| 2015 | $1.3B | $658.5M | $1.4B | +108% |
| 2014 | $649.1M | $576M | $979.5M | −6% |
| 2013 | $688.6M | $241.4M | $726.9M | +169% |
| 2012 | $256.1M | $142.2M | $265.7M | +76% |
| 2011 | $145.6M | $134.6M | $192.6M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Ligand Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| LGNDLigand Pharmaceuticals | $6.1B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| KNSAKiniksa Pharmaceuticals International | $7.1B |
| ALKSAlkermes plc. | $7.5B |
| CORTCorcept Therapeutics | $8.7B |
| INDVIndivior Pharmaceuticals | $4.3B |
| PTGXProtagonist Therapeutics | $9B |
| TGTXTG Therapeutics | $9.2B |
| ARQTArcutis Biotherapeutics | $3.9B |
| LQDALiquidia | $3.7B |
| OGNOrganon | $3.6B |
| Peer median | $6.8B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Ligand Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.